Spatial heterogeneity of antibody-drug conjugate targets in pancreatic ductal adenocarcinoma - PubMed
6 hours ago
- #Pancreatic Cancer
- #Spatial Heterogeneity
- #Antibody-Drug Conjugates
- Study examines spatial heterogeneity of ADC targets (c-MET, NECTIN4, TROP-2) in PDAC.
- c-MET shows higher expression at tumor front vs. center with notable heterogeneity.
- NECTIN4 is absent in ~2/3 of cases; TROP-2 shows strong, homogeneous positivity (98% 3+).
- Sampling sufficiency varies: c-MET (2 samples for 1+, 4 for 2+/3+), NECTIN4 (4 for 1+/2+), TROP-2 (2 for 3+).
- NECTIN4 expression correlates with tumor grade; TROP-2 inversely correlates with PD-L1.
- No significant expression differences found between SMAD4 or TP53 wild-type/mutated tumors.
- Metastases show higher c-MET and NECTIN4 expression compared to primary tumors.
- TROP-2 is highly expressed in most PDACs, making it an ideal ADC target.